Zhang Haijiao, Paliga Aleksandra, Hobbs Evie, Moore Stephen, Olson Susan, Long Nicola, Dao Kim-Hien T, Tyner Jeffrey W
Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon 97239, USA.
Division of Hematology and Medical Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon 97239, USA.
Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6). doi: 10.1101/mcs.a003079. Print 2018 Dec.
Genetic rearrangements involving are rare and only recently have been detected in myeloid/lymphoid neoplasms associated with eosinophilia (MLN-eos) and chronic myeloproliferative disorders. Here we report two cases with fusions in patients demonstrating mixed features of myelodysplastic/myeloproliferative neoplasms. In the first case, was fused with a new fusion partner in a patient with marrow features most consistent with atypical chronic myeloid leukemia; the second case involving - fusion was observed in a case with bone marrow features most consistent with chronic myelomonocytic leukemia. Notably, we observed that samples from both patients demonstrated FLT3 inhibitor (quizartinib and sorafenib) sensitivity in ex vivo drug screening assay.
涉及的基因重排很少见,直到最近才在与嗜酸性粒细胞增多相关的髓系/淋系肿瘤(MLN-eos)和慢性骨髓增殖性疾病中被检测到。在此,我们报告了两例有融合的病例,这些患者表现出骨髓增生异常/骨髓增殖性肿瘤的混合特征。在第一例中,在一名骨髓特征最符合非典型慢性髓性白血病的患者中,与一个新的融合伴侣融合;第二例涉及融合的病例在一名骨髓特征最符合慢性粒单核细胞白血病的患者中被观察到。值得注意的是,我们观察到两名患者的样本在体外药物筛选试验中均表现出对FLT3抑制剂(quizartinib和sorafenib)敏感。